Stanley Druckenmiller’s AstraZeneca AZN Stock Holding History

Stanley Druckenmiller’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-208,900	Closed	-$15.5M	–	39
2014 Q2	$15.5M	Sell	208,900 -151,600	-42%	-$11M	1.11%	28
2014 Q1	$23.4M	Hold	360,500	–	–	2.64%	10
2013 Q4	$21.4M	Buy	+360,500	New	+$19.6M	1.43%	26

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Stanley Druckenmiller's AZN Position: Q3 2014 in Review

Stanley Druckenmiller sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 208,900 shares — an estimated $15.5M sold.

Stanley Druckenmiller first reported a position in AZN in Q4 2013 and held it in 3 quarters. The position peaked at $23.4M in Q1 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

Stanley Druckenmiller reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
Stanley Druckenmiller sold 208,900 AstraZeneca shares in Q3 2014, an estimated $15.5M.
Stanley Druckenmiller first reported a position in AstraZeneca in Q4 2013 and held it in 3 quarters.
Stanley Druckenmiller's AstraZeneca position peaked at $23.4M in Q1 2014.
402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Duquesne Family Office's 13F filing for Q3 2014, filed 14 Nov 2014.